Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Headlands Technologies LLC

Headlands Technologies LLC reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 89.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,793 shares of the biopharmaceutical company's stock after selling 69,094 shares during the quarter. Headlands Technologies LLC's holdings in Pfizer were worth $207,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock worth $13,756,738,000 after acquiring an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC boosted its stake in Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares during the period. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth about $2,328,986,000. Finally, Van ECK Associates Corp increased its holdings in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock valued at $564,739,000 after purchasing an additional 4,726,549 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Pfizer Stock Down 5.4 %

NYSE:PFE traded down $1.30 on Friday, reaching $22.99. The stock had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The company has a 50-day moving average of $25.87 and a 200 day moving average of $26.76. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $130.39 billion, a P/E ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $22.95 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. Pfizer's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on PFE. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.